Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-01-02 | Reverse | 1:20 |
Pasithea Therapeutics Corp. is a Miami Beach-based biotech founded in 2020, focused on developing treatments for psychiatric and neurological disorders, including ketamine infusion clinics and related support services.

PAS-004 is a next-generation macrocyclic MEK inhibitor in Phase 1/1b trials, developed to treat RASopathies like NF1 and MAPK pathway-driven tumors.
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
CYCN | $4.20 | COMPARE |
QNRX | $7.22 | COMPARE |
PLRZ | $12.30 | COMPARE |
KALA | $0.51 | COMPARE |
TCRT | $1.61 | COMPARE |
VIVS | $0.28 | COMPARE |